|
|
Volumn 11, Issue 2, 2000, Pages 131-132
|
|
The prognosis of prognostic factors in phase I clinical trials
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYTOTOXIC AGENT;
DOXORUBICIN;
GLYCOPROTEIN P;
CANCER;
CANCER INHIBITION;
CANCER REGRESSION;
CANCER SURVIVAL;
CLINICAL STUDY;
DRUG SAFETY;
DRUG SCREENING;
EDITORIAL;
HUMAN;
MAXIMUM PERMISSIBLE DOSE;
PRIORITY JOURNAL;
PROGNOSIS;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE I;
CONFIDENCE INTERVALS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
FEMALE;
HUMANS;
MALE;
NEOPLASMS;
PROGNOSIS;
RISK FACTORS;
SENSITIVITY AND SPECIFICITY;
SURVIVAL ANALYSIS;
|
|
EID: 0034013210
PISSN: 09237534
EISSN: None
Source Type: Journal
DOI: 10.1023/A:1008327527877 Document Type: Editorial |
|
Times cited : (5)
|
|
References (8)
|
